Improving the Outlook for Heart Failure: Incorporating New Agents and New Guidance

The number of Americans with heart failure (HF) is growing. Management of these patients is complex, with an increasing number of approved agents and the need to use several drugs, achieve target dosing, and manage side effects. Some of agents are relatively new, so cardiologists need information about these agents and how best to incorporate them into the management of patients with HFrEF. In addition, several agents are in late-stage development and are expected to be approved soon.

The educational program “Improving the Outlook for Heart Failure: Incorporating New Agents and New Guidance” will provide cardiologists with information about the most recent evidence-based recommendations for managing HFrEF including incorporating newer agents into management strategies and about the mechanism of action, efficacy, and safety of newer approved agents and those agents for which approval is anticipated in the near future.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Merck & Co, Inc.

Click here for the PCME Privacy Policy